Scarica l'app Stockscreener
28.00
3.61%
-1.05
Dopo l'orario di chiusura:
27.91
-0.09
-0.32%
Precedente Chiudi:
$29.05
Aprire:
$28.93
Volume 24 ore:
328.16K
Relative Volume:
1.01
Capitalizzazione di mercato:
$723.53M
Reddito:
-
Utile/perdita netta:
$-184.46M
Rapporto P/E:
-0.1962
EPS:
-142.7277
Flusso di cassa netto:
$-24.11M
1 W Prestazione:
-18.84%
1M Prestazione:
-18.89%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$27.60
$28.93
Intervallo di 1 settimana:
$27.60
$34.81
Portata 52W:
$17.50
$42.14
Faeth Therapeutics Inc Stock (FTH) Company Profile
Nome
Faeth Therapeutics Inc
Settore
Industria
Telefono
(240) 243-8000
Indirizzo
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
28.00 | 723.53M | 0 | -184.46M | -24.11M | -142.73 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Faeth Therapeutics Inc Borsa (FTH) Ultime notizie
Faeth Therapeutics Adds Cancer Expert to Board - TipRanks
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to S&P Biotechnology Select Industry Index - marketscreener.com
Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion - Seeking Alpha
Faeth Therapeutics appoints Karen Vousden to board By Investing.com - Investing.com Nigeria
Faeth Therapeutics (FTH) Adds Renowned Cancer Biologist Dr. Kare - gurufocus.com
Faeth Therapeutics appoints Karen Vousden to board - Investing.com
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors - Yahoo Finance
Faeth stock gets new Buy at Guggenheim (FTH:NASDAQ) - Seeking Alpha
Faeth Therapeutics at Morgan Stanley conference: oral cancer strategy By Investing.com - Investing.com Nigeria
FTH Initiated Coverage by Guggenheim -- Price Target Announced a - GuruFocus
Faeth Therapeutics Director Karen H. Vousden Granted 25,000 Stock Options - Kalkine Media
Faeth Therapeutics (FTH) awards 25,000 stock options to director - stocktitan.net
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
FTH Initiates Coverage On by Lucid Capital Markets -- Price Targ - GuruFocus
Faeth Therapeutics at Cantor Fitzgerald conference: oral PI3K push By Investing.com - Investing.com Canada
A booming business on Wall Street would love more biotechs to quietly die - BioPharma Dive
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
FTH Initiated Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating - Yahoo Finance
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 - BioSpace
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
Faeth Therapeutics stock hits 52-week high at 40.89 USD By Investing.com - Investing.com Australia
Faeth Therapeutics stock hits 52-week high at 40.89 USD - investing.com
Bullish Faeth Therapeutics Insiders Rewarded As Their Investment Rises To US$1.94m - simplywall.st
Insiders of Faeth Therapeutics Getting Good Value On Their US$1.19m Investment - Moomoo
Biotech Stocks At 52-Week HighsOABI +13%, FRNM, EXEL, FTH, LFST - RTTNews
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? - Eastern Progress
Faeth Therapeutics to Participate in Upcoming September Investor Conferences - Business Wire
Faeth Therapeutics (FTH) Grants Stock Options to New Hires Amid Unprofitable Growth Phase - GuruFocus
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Capital expenditures of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know - Yahoo Finance
FAETH THERAPEUTICS, INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $56 - Bitget
Needham initiates Faeth Therapeutics stock with buy rating on cancer drug potential - Investing.com Canada
FTH Initiates Coverage On by Needham -- Buy Rating with $56 Pric - GuruFocus
Needham Initiates Faeth Therapeutics at Buy With $56 Price Target - Yahoo Finance
Khosla Ventures Seed Associates D, Llc Net Worth (2026) - GuruFocus
Why is Faeth Therapeutics stock surging today? By Investing.com - Investing.com Canada
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - BioSpace
FDA grants fast track status to Faeth’s endometrial cancer drug - Investing.com
Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Ca - GuruFocus
FDA grants fast track status to Faeth’s endometrial cancer drug By Investing.com - Investing.com Canada
Faeth Therapeutics Gets US FDA Fast Track Designation for Endometrial Cancer Drug Combination - Yahoo Finance
FTH: Faeth Therapeutics, Inc.Insider Transations - Zacks Investment Research
Faeth TherapeuticsFTHStock Price & News - fool.com
Faeth Therapeutics (FTH) investor Caligan reports 2.4% stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH) investor Trails Edge reports 2.0% beneficial stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH): Khosla Ventures group discloses 10.2% ownership stake - Stock Titan
Faeth Therapeutics, Inc. (NASDAQ: FTH) Share Price, FTH Stock News, FTH Share Price & Updates - kalkine.ca
PR News | On the Move: Finn Names Flach PartnerFri., Aug. 14, 2026 - O'Dwyer's PR
Faeth Therapeutics Inc Azioni (FTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):